References:
- Anstey A, Lear JT: Azathioprine: clinical pharmacology and current
indications in autoimmune disorders. BioDrugs . 1998
Jan;9(1):33-47.
- Dubinsky MC: Azathioprine, 6-mercaptopurine in inflammatory bowel
disease: pharmacology, efficacy, and safety. Clin Gastroenterol
Hepatol . 2004 Sep;2(9):731-43.
- Bär F, Sina C, Fellermann K. Thiopurines in inflammatory bowel disease
revisited. World J Gastroenterol. 2013;19:1699-706.
- Ladrière M. [Current indications of azathioprine in nephrology].Nephrol Ther . 2013 Feb;9(1):8-12.
- Wee JS, Marinaki A, Smith CH. Life threatening myelotoxicity secondary
to azathioprine in a patient with atopic eczema and normal thiopurine
methyltransferase activity. BMJ. 2011 Mar 25;342:d1417.
- Avallone EV, Pica R, Cassieri C, Zippi M, Paoluzi P, Vernia P.
Azathioprine treatment in inflammatory bowel disease patients: type
and time of onset of side effects. Eur Rev Med Pharmacol Sci. 2014;
18(2): 165–70.
- Macaluso FS, Renna S, Maida M, Dimarco M, Sapienza C, Affronti M, et
al. Tolerability profile of thiopurines in inflammatory bowel disease:
a prospective. experience. Scand J Gastroenterol. 2017;52:981-7.
- Alves da Silva JI;Caetano C;Pedroto I; (n.d.).Azathioprine-induced acute submandibular sialadenitis in a
crohn’s disease patient . GE Portuguese journal of gastroenterology.
2020 Aug; 27(5): 361–363.
- Vinayak V, Annigeri RG, Patel HA, Mittal S. Adverse affects of drugs
on saliva and salivary glands. J Orofac
Sci. 2013;5((1)):15–20.
- Hanauer SB, Sandborn WJ, Lichtenstein GR. Evolving considerations for
thiopurine therapy for inflammatory bowel diseases – a clinical
practice update: commentary. Gastroenterology. 2019 Jan; 156(1):
36–42.
- Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, Miehlke S, et al.;
German IBD Study Group. Azathioprine-induced acute pancreatitis in
patients with inflammatory bowel diseases – a prospective study on
incidence and severity. J Crohns Colitis. 2016 Jan; 10(1):61–8.
- Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse
events leading to modification of therapy in a large cohort of
patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2006
Jul; 24(2): 331–42.
- Krishnamurthy S, Vasudeva SB, Vijayasarathy S. Salivary gland
disorders: a comprehensive review. World J Stomatol. 2015;4:56-71.
- Wolff A, Joshi RK, Ekström J, Aframian D, Pedersen AM, Proctor G, et
al. A Guide to Medications Inducing Salivary Gland Dysfunction,
Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored
by the World Workshop on Oral Medicine VI. Drugs R D. 2017 Mar; 17(1):
1–28.
- Vinayak V, Annigeri RG, Patel HA, Mittal S. Adverse affects of drugs
on saliva and salivary glands. J Orofac Sci. 2013; 5(1): 15–20.